Press coverage about Fluidigm Corporation (NASDAQ:FLDM) has been trending somewhat positive on Tuesday, Alpha One reports. Alpha One, a subsidiary of Accern, identifies positive and negative press coverage by monitoring more than 20 million news and blog sources. Alpha One ranks coverage of public companies on a scale of negative one to positive one, with scores nearest to one being the most favorable. Fluidigm Corporation earned a news impact score of 0.25 on Alpha One’s scale. Alpha One also gave news stories about the medical research company an impact score of 76 out of 100, indicating that recent press coverage is likely to have an effect on the company’s share price in the next few days.
Several equities research analysts recently issued reports on the stock. Zacks Investment Research upgraded shares of Fluidigm Corporation from a “sell” rating to a “hold” rating in a report on Thursday, June 1st. ValuEngine cut shares of Fluidigm Corporation from a “sell” rating to a “strong sell” rating in a report on Friday, June 2nd.
Fluidigm Corporation (FLDM) traded down 0.80% on Tuesday, reaching $3.74. 19,592 shares of the company’s stock traded hands. The stock’s market cap is $109.56 million. Fluidigm Corporation has a 12-month low of $3.54 and a 12-month high of $10.94. The stock has a 50 day moving average price of $4.85 and a 200 day moving average price of $5.91.
In other Fluidigm Corporation news, Director Evan/ Fa Jones sold 10,900 shares of the firm’s stock in a transaction that occurred on Wednesday, June 7th. The shares were sold at an average price of $4.54, for a total transaction of $49,486.00. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. Also, Director Samuel D. Colella acquired 7,500 shares of the business’s stock in a transaction on Tuesday, May 9th. The shares were bought at an average cost of $5.93 per share, for a total transaction of $44,475.00. Following the acquisition, the director now owns 43,523 shares of the company’s stock, valued at approximately $258,091.39. The disclosure for this purchase can be found here. 4.50% of the stock is currently owned by company insiders.
ILLEGAL ACTIVITY NOTICE: This piece of content was published by Stock Observer and is the sole property of of Stock Observer. If you are accessing this piece of content on another publication, it was illegally copied and reposted in violation of United States and international copyright laws. The correct version of this piece of content can be read at https://www.thestockobserver.com/2017/06/20/fluidigm-fldm-given-coverage-optimism-score-of-0-25-updated-updated.html.
About Fluidigm Corporation
Fluidigm Corporation creates, manufactures and markets technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company operates in the development, manufacturing and commercialization of life science tools for the life science and Ag-Bio industries segment.
Receive News & Ratings for Fluidigm Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm Corporation and related companies with MarketBeat.com's FREE daily email newsletter.